Jacqueline van der Spuy

Prof. Jacqueline van der Spuy

University College London Institute of Ophthalmology, London, City of London, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Current Biology
Verified
Journal Article
Closed access
BWBritta Westhoff
Britta Westhoff
PCPaul Chapple
Paul Chapple
JSJacqueline van der Spuy
Jacqueline van der Spuy
JHJörg Höhfeld
Jörg Höhfeld
MCMichael E. Cheetham
Michael E. Cheetham

9 December 2014
Verified
Book Chapter
Closed access
PDF file
EDEmma J. Duncan
Emma J. Duncan
MCMichael E. Cheetham
Michael E. Cheetham
PCPaul Chapple
Paul Chapple
JSJacqueline van der Spuy
Jacqueline van der Spuy

1 July 2008 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
JHJuan Hidalgo-De-Quintana
Juan Hidalgo-De-Quintana
RER. Jane Evans
R. Jane Evans
MCMichael E. Cheetham
Michael E. Cheetham
JSJacqueline van der Spuy
Jacqueline van der Spuy
Purpose. AIPL1 mutations cause the severe inherited blindness Leber congenital amaurosis (LCA). The similarity of AIPL1 to tetratricopeptide repeat (TPR) cochaperones that interact with the chaperone Hsp90 and the ability of AIPL1 to suppress the aggregation of NUB1 fragments in a chaperone-like manner suggest that AIPL1 might function as part of a chaperone heterocomplex facilitating retinal protein maturation. In this study the interaction of AIPL1 with molecular chaperones is revealed and functionally characterized. methods. AIPL1-interacting proteins were identified using a yeast two-hybrid system, and the effect of AIPL1 pathogenic mutations and sequence requirements mediating the identified interactions were investigated. The interactions were validated by a comprehensive set of biochemical assays, and the ability of the AIPL1-binding partners to cooperate with AIPL1 in the suppression of NUB1 fragment aggregation was assessed. results. AIPL1 interacts with the molecular chaperones Hsp90 and Hsp70. Mutations within the TPR domain of AIPL1 or removal of the chaperone TPR acceptor site abolished the interactions. Importantly, LCA-causing mutations in AIPL1 also compromised these interactions, suggesting that the essential function of AIPL1 in photoreceptors may involve the interaction with Hsp90 and Hsp70. Examination of the role of these chaperones in AIPL1 chaperone activity demonstrated that AIPL1 cooperated with Hsp70, but not with Hsp90, to suppress the formation of NUB1 inclusions. conclusions. These findings suggest that AIPL1 may cooperate with both Hsp70 and Hsp90 within a retina-specific chaperone heterocomplex and that the specialized role of AIPL1 in photoreceptors may therefore be facilitated by these molecular chaperones.

10 September 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EREmma Richet
Emma Richet
APAmy M. Pooler
Amy M. Pooler
TRTeresa Rodriguez
Teresa Rodriguez
SNSergey S. Novoselov
Sergey S. Novoselov
GSGunter Schmidtke
Gunter Schmidtke
JSJacqueline van der Spuy
Jacqueline van der Spuy
Abnormal phosphorylation of the microtubule-associated protein tau in neurodegenerative disorders, including Alzheimer's disease (AD) and frontotemporal lobar degeneration, is associated with disrupted axonal transport and synaptic dysfunction ultimately manifesting as histopathological lesions of protein aggregates. Glycogen synthase kinase 3β (GSK3β) may be critical for the pathological hyperphosphorylation of tau. Here, we examined the role of the proteasome-associated protein Nedd8 ultimate buster 1 (NUB1) in the neuropathogenic phosphorylation and aggregation of tau. We reveal that NUB1 interacted with both tau and GSK3β to disrupt their interaction, and abolished recruitment of GSK3β to tau inclusions. Moreover, NUB1 reduced GSK3β-mediated phosphorylation of tau and aggregation of tau in intracellular inclusions. Strikingly, NUB1 induced GSK3β degradation. Deletion of the NUB1 ubiquitin-like (UBL) domain did not impair the interaction with tau and GSK3β, and the ability to suppress the phosphorylation and aggregation of tau was not affected. However, the UBL motif was necessary for GSK3β degradation. Deletion of the NUB1 ubiquitin-associated (UBA) domain abrogated the ability of NUB1 to interact with and degrade GSK3β. Moreover, the UBA domain was required to suppress the aggregation of tau. Silencing of NUB1 in cells stabilized endogenous GSK3β and exacerbated tau phosphorylation. Thus, we propose that NUB1, by regulating GSK3β levels, modulates tau phosphorylation and aggregation, and is a key player in neurodegeneration associated with tau pathology. Moreover, NUB1 regulation of GSK3β could modulate numerous signalling pathways in which GSK3β is a centrally important effector.

7 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
JSJulio Cesar Corral Serrano
Julio Cesar Corral Serrano
PSPaul E. Sladen
Paul E. Sladen
DODaniele Ottaviani
Daniele Ottaviani
OROlivia F. Rezek
Olivia F. Rezek
DADimitra Athanasiou
Dimitra Athanasiou
MCMichael E. Cheetham
Michael E. Cheetham
The photoreceptor outer segment is a highly specialized primary cilium that is essential for phototransduction and vision. Biallelic pathogenic variants in the cilia-associated gene CEP290 cause non-syndromic Leber congenital amaurosis 10 (LCA10) and syndromic diseases, where the retina is also affected. While RNA antisense oligonucleotides and gene editing are potential treatment options for the common deep intronic variant c.2991+1655A>G in CEP290, there is a need for variant-independent approaches that could be applied to a broader spectrum of ciliopathies. Here, we generated several distinct human models of CEP290-related retinal disease and investigated the effects of the flavonoid eupatilin as a potential treatment. Eupatilin improved cilium formation and length in CEP290 LCA10 patient-derived fibroblasts, in gene-edited CEP290 knockout (CEP290 KO) RPE1 cells, and in both CEP290 LCA10 and CEP290 KO iPSCs-derived retinal organoids. Furthermore, eupatilin reduced rhodopsin retention in the outer nuclear layer of CEP290 LCA10 retinal organoids. Eupatilin altered gene transcription in retinal organoids by modulating the expression of rhodopsin and by targeting cilia and synaptic plasticity pathways. This work sheds light on the mechanism of action of eupatilin and supports its potential as a variant-independent approach for CEP290-associated ciliopathies.

8 September 2022 in Stem Cell Reports
Verified
Journal Article
Open access
ALAmy Leung
Amy Leung
ASAlmudena Sacristan-Reviriego
Almudena Sacristan-Reviriego
PPPedro R.L. Perdigão
Pedro R.L. Perdigão
HSHali Sai
Hali Sai
MGMichalis Georgiou
Michalis Georgiou
JSJacqueline van der Spuy
Jacqueline van der Spuy
Leber congenital amaurosis type 4 (LCA4), caused by AIPL1 mutations, is characterized by severe sight impairment in infancy and rapidly progressing degeneration of photoreceptor cells. We generated retinal organoids using induced pluripotent stem cells (iPSCs) from renal epithelial cells obtained from four children with AIPL1 nonsense mutations. iPSC-derived photoreceptors exhibited the molecular hallmarks of LCA4, including undetectable AIPL1 and rod cyclic guanosine monophosphate (cGMP) phosphodiesterase (PDE6) compared with control or CRISPR-corrected organoids. Increased levels of cGMP were detected. The translational readthrough-inducing drug (TRID) PTC124 was investigated as a potential therapeutic agent. LCA4 retinal organoids exhibited low levels of rescue of full-length AIPL1. However, this was insufficient to fully restore PDE6 in photoreceptors and reduce cGMP. LCA4 retinal organoids are a valuable platform for in vitro investigation of novel therapeutic agents.